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In this paper we demonstrate that patients treated with chemotherapy and/or hematopoietic stem cell
transplantation (HSCT) have highly signiﬁcant reduced serum ascorbic acid (AA) levels compared to
healthy controls. We recently observed in in vitro experiments that growth of both T and NK cells from
hematopoietic stem cells is positively inﬂuenced by AA. It might be of clinical relevance to study the
function and recovery of immune cells after intensive treatment, its correlation to AA serum levels and
the possible effect of AA supplementation.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vitamin C or ascorbic acid (AA), an essential water-soluble vitamin
with many functions [1,2], has a crucial role in cellular immune
responses [3]. Patients treated with intensive chemotherapy and/or
hematopoietic stem cell transplantation (HSCT) have low immune cell
counts for weeks to months [4]. Meanwhile, patients are highly sus-
ceptible to infections resulting in morbidity and mortality. We recently
observed that in the presence of AA, early hematopoietic progenitors
commit and mature into T cells and proliferate faster [5]. Moreover, we
showed that AA enhances proliferation andmaturation of NK cells [6]. As
AA has a major inﬂuence on (re)generation of immune cells in vitro, we
executed an observational study in which AA serum values of patients
with hematological malignancies treated with and without HSCT were
comparedwith those of healthy volunteers to see if low AA levels should
be considered of importance regarding immune recovery of these
patients.B.V. This is an open access article u
cine, Division of Hematology,
gel 50, P.O. Box 616, 6200 MD
y.nl (W.T.V. Germeraad).2. Materials and methods
2.1. Patients and controls
Basic patient characteristics are shown in Table 1.
AA levels were measured in 42 non-selected hemato-oncology
patients admitted to the hospital because of treatment or com-
plications. Samples were taken of all patients admitted on the day
routine blood samples are taken. Therefore, the patient population
is a mixture of all type of patients as well as stages of disease and
treatment. As control group, healthy volunteers (N¼79, mean
age¼36.87 (range 20–63) working in the hospital donated blood
samples for clotting parameter reference values of our laboratory.
This study was performed in accordance with the Declaration of
Helsinki and according to Dutch Code for Proper Secondary Use of
Human Tissue [7].
Patients receiving autologous HSCT had the following diseases and
treatment: MM (6; conditioning with high dose Melfalan); NHL (3;
condition with BEAM) and AML (1, conditioning with Busulphan and
Cyclophosfamide). Patients receiving an allogeneic HSCT had the fol-
lowing diseases and treatment: AML (7); ALL (2); NHL (4); CLL (1);
CML (1); Myeloﬁbrosis (1). All were treated with a non-myeloablative
conditioning regimen (Fludarabine with low dose total body irradia-
tion with or without anti-thymocyte globulin (Rabbit ATG, 2 mg/kg)nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characteristics of the patients.
Patient characteristics HSCT Non-HSCT Total
n 26 16 42
Sex; male/female 15/11 7/9 22/20
Age; median (range), year 56.5 (39–72) 62.5 (40–71) 59 (39–72)
Disease
AML 8 8 16
ALL 2 2 4
CML 1 1
CLL 1 2 3
MM 6 6
Myeloﬁbrosis 1 1
NHL 7 4 11
HSCT
Autologous 10
Allogeneic 16
GVHD 7
HSCT: Hematopoietic stem cell transplantation; AML: Acute Myeloid Leukemia;
ALL: Acute Lymphatic Leukemia; CML: Chronic Myeloid Leukemia; CLL: Chronic
Lymphoid Leukemia; MM: Multiple Myeloma; NHL: non-Hodgkin Lymphoma;
GVHD: Graft versus host disease. The non-transplanted patients were all admitted
for chemotherapy treatment, except for one patient with CLL that was treated with
prednisone only. The patients with MM and autologous transplantation were
conditioned with high dose Melphalan and the patient with NHL undergoing
autologous transplantation received BEAM conditioning. All patients undergoing
donor transplantation were treated with Fludarabine and low dose total body
irradiation, with or without anti-thymocyte globulin, depending on the Human
Leukocyte Antigen mismatch. Only the one patiento40 years of age was treated
with intensive chemotherapy regimen (Busulfan and Cyclophosphamide).
M.J.A.J. Huijskens et al. / Results in Immunology 6 (2016) 8–10 9depending on the Human Leukocyte Antigen mismatch), except for
one patient with AML who was treated with intensive chemotherapy
(Busulfan and Cyclophosfamide).0
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Fig. 1. Serum ascorbic acid levels. A: Serum ascorbic acid values of controls and patients a
For seven patients with undetectable AA levels (o10 μMol/L), 10 μMol/L was appointed
The regression coefﬁcient of AA comparing healthy controls to patients with hematologic
age and sex, being 34.4 mMol/L (95%CI 43.04 to 25.81) with po0.0001 comparing
(p¼0.63). D: Serum AA values of allogeneic versus autologous HSCT. Signiﬁcance was test
allogeneic HSCT patients suffering from GVHD or not (p¼0.87). F: Serum ascorbic acid2.2. Ascorbic acid measurements
Serum AA was indirectly determined by measuring ferrous ion
and 2,4,6-tris(2-pyridyl)-s-triazine (Fe2þ-TPTZ, Sigma-Aldrich,
Zwijndrecht, the Netherlands). This reaction product is formed by
nonspeciﬁc reduction of the corresponding ferric ion complex
(Fe3þ-TPTZ) by biological reducing agents such as AA at pH 3.6. AA
was speciﬁcally quantiﬁed by pretreating one of a pair of replicate
samples with the enzyme Ascorbate oxidase (Sigma-Aldrich),
oxidizing AA to dehydroascorbic acid, then reacting both samples
with Fe3þ-TPTZ and measuring the difference in absorbances at
600 nm on the Cobas Mira Plus (Roche, Basel, Switzerland). The AA
concentration was calculated from a standard addition curve with
a 10 mMol/L detection limit.
2.3. Statistical analysis
Data are represented as median with corresponding inter-
quartile range and compared with the Mann–Whitney U test; a
po0.05 was considered statistically signiﬁcant. Determinants of
AA serum levels were corrected with multivariable regression
analysis. Analyses were performed with Prism (GraphPad Software
Inc) and IBM SPSS (SPSS).3. Results
Healthy volunteers had serum AA levels of 65mMol/L (median,
95%CI 61.56-69.46), while a signiﬁcant decrease was observed in
patients with hematological malignancies who had AA serum
levels of 20.5 mMol/L (median, 95%CI 21.27–32.68, Fig. 1A). Eight
patients (19% of total patients) had AA serum values o11.4 μMol0
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re represented as mMol/L. Data were compared with Mann–Whitney U (po0.0001).
as AA value. B: Age (years) and serum AA values (mMol/L) of controls and patients.
al malignancies is 38.5 mMol/L AA (95%CI 45.29 to 31.78). After correction for
controls and patients. C: Serum AA values (mMol/L) of HSCT and non-HSCT patients
ed with Mann Whitney U test and results in p¼0.83. E: Serum AA values (mMol/L) of
values of HSCT patients plotted to day of AA measurement after HSCT (p¼0.58).
M.J.A.J. Huijskens et al. / Results in Immunology 6 (2016) 8–1010and are considered to be AA deﬁcient [8]. The patient group was
signiﬁcantly older than the control group (mean 57.2 vs. 36.87,
respectively). After correction with multivariable regression ana-
lysis for age and sex the difference in serum AAwas still signiﬁcant
(po0.0001, Fig. 1B).
Within the patient group (although subgroup sizes are small),
patients treated with HSCT or chemotherapy/prednisone did not
have signiﬁcantly different serum AA values, nor was there a dif-
ference between patients after autologous transplantation with
high dose chemotherapy or allogeneic transplantation with non-
myeloablative conditioning for all except one patient (Fig. 1C and
D). Furthermore, within the allogeneic HSCT group, no difference
was observed in patients suffering from GVHD (Fig. 1E).
Additionally, low serum AA values were not only observed
during the acute phase of disease but even up to 360 days after
transplantation in a patient admitted because of GVHD (Fig. 1F).4. Discussion
In this preliminary analysis we demonstrate that patients with
a hematological malignancy, either treated with chemotherapy or
with autologous or allogeneic HSCT might have highly signiﬁcant
reduced serum AA levels as compared to controls. Recently, it was
shown that patients receiving allogeneic HSCT have low serum AA
in the acute phase post-transplantation [9]. We show that low AA
levels are also present in the chronic phase post-transplantation.
Furthermore, our ﬁndings are not limited to HSCT patients, but are
also convincing for non-transplanted patients.
Human AA levels depend on dietary intake; therefore limited
food intake following treatment may explain the observed vitamin
C deﬁciency. Moreover, impaired metabolism is observed in cancer
patients [10]. In general patients with any illness might have lower
AA levels. Of the 382 AA measurements performed in our hospital
between 2010 and 2014, 30 patients (8%) had a low AA level,
indicating that not only patients with hematological diseases (19%)
might have low vitamin levels (data not shown). This could be
related to the disease itself or the stage of the disease of the
patients. It seems that cancer patients have lower AA levels than
patients suffering from other diseases.
Although AA serum levels in the patients are low, it should be
considered that intracellular levels of AA in leukocytes might not
be reﬂected by serum levels since immune cells might accumulate
AA [11]. However, serum measurements are the current gold
standard and it is accepted that values o11.4 μMol/L indicate
vitamin C deﬁciency though reference values for normal vitamin C
levels are scarce, and might partly depend on the methodology
used. No separate reference values are available for our region
[8,12]. According to these values, a vitamin C deﬁciency is present
in a substantial proportion of our patient group. Serum AA values
of patients with GVHD after allogeneic HSCT – all with the gas-
trointestinal tract involved –were not further decreased compared
to patients without GVHD, with the limitation of small group sizes
and therefore with a small power to detect differences.
Since AA might be crucial for immune function and for in vitro
development and expansion of T and NK cells from stem cells [5,6],
we are currently studying the function and recovery of immune
cells while patients are on treatment for various malignancies, and
determine the correlation of AA serum and leukocyte levels and
the possible effect of vitamin C supplementation. Not only inpatients with intensive chemotherapy regimens but also with less
intensive regimens, where recovery of granulocytes is often a
limiting factor for adequate dosing of chemotherapy regimens
responsible for substantial morbidity [13,14].Disclosures
The authors declare no conﬂict of interest.Acknowledgments
The authors would like to thank Rene van Oerle, Department of
Biochemistry, Maastricht University for supplying the samples of
the control group. This work was supported by Grant UM2010-
4671 from the Dutch Cancer Society KWF and with ﬁnancial
support (project killer cells) from the Cancer Research Fund Lim-
burg. These organizations had no inﬂuence on the content of
the work.References
[1] S. Englard, S. Seifter, The biochemical functions of ascorbic acid, Annu. Rev.
Nutr. 6 (1986) 365–406.
[2] A. Monfort, A. Wutz, Breathing-in epigenetic change with vitamin C, EMBO
Rep. 14 (4) (2013) 337–346, http://dx.doi.org/10.1038/embor.2013.29.
[3] A. Strohle, M. Wolters, A. Hahn, Micronutrients at the interface between
inﬂammation and infection-ascorbic acid and calciferol. Part 2: calciferol and
the signiﬁcance of nutrient supplements, Inﬂamm. Allergy Drug Targets 10 (1)
(2011) 64–74.
[4] M. Bosch, M. Dhadda, M. Hoegh-Petersen, Y. Liu, L.M. Hagel, P. Podgorny, et al.,
Immune reconstitution after anti-thymocyte globulin-conditioned
hematopoietic cell transplantation, Cytotherapy 14 (10) (2012) 1258–1275.
[5] M.J.A.J. Huijskens, M. Walczak, N. Koller, J. Briedé, B.L.M.G. Senden-Gijsbers, M.
C. Schnijderberg, et al., Ascorbic acid induces development of double-positive
T cells from human hematopoietic stem cells in the absence of stromal cells, J.
Leukoc. Biol. 96 (6) (2014) 1165–1175, http://dx.doi.org/10.1189/jlb.
[6] M.J.A.J. Huijskens, M. Walczak, S. Sarkar, F. Atraﬁ, B.L.M.G. Senden-Gijsbers,
M. Tilanus, et al., Ascorbic acid promotes proliferation of NK cell populations
in different culture systems applicable for NK cell therapy, Cytotherapy 17 (5)
(2015) 613–620, http://dx.doi.org/10.1016/j.jcyt.2015.01.004.
[7] The Code for Proper Secondary Use of Human Tissue. 〈http://www.federa.org/
sites/default/ﬁles/bijlagen/coreon/codepropersecondaryuseofhumantissue1_
0.pdf〉, Nov 2014.
[8] R.L. Schleicher, M.D. Carroll, E.S. Ford, D.A. Lacher, Serum vitamin C and the
prevalence of vitamin C deﬁciency in the United States: 2003–2004 National
Health and Nutrition Examination Survey (NHANES), Am. J. Clin. Nutr. 90 (5)
(2009) 1252–1263.
[9] Y. Nannya, A. Shinohara, M. Ichikawa, M. Kurokawa, Serial proﬁle of vitamins
and trace elements during the acute phase of allogeneic stem cell transplan-
tation, Biol. Blood Marrow Transpl. 20 (3) (2014) 430–434.
[10] G. Nitenberg, B. Raynard, Nutritional support of the cancer patient: issues and
dilemmas, Crit. Rev. Oncol. Hematol. 34 (3) (2000) 137–168.
[11] A. Strohle, M. Wolters, A. Hahn, Micronutrients at the interface between
inﬂammation and infection–ascorbic acid and calciferol: part 1, general
overview with a focus on ascorbic acid, Inﬂamm. Allergy Drug Targets 10 (1)
(2011) 54–63.
[12] H. Hooijkaas, K. Mohrmann, L. Smeets, J. Souverijn, Handboek medische
laboratoriumdiagnostiek, tweede herziene druk, 2013.
[13] S.J. Padayatty, H. Sun, Y. Wang, H.D. Riordan, S.M. Hewitt, A. Katz, et al.,
Vitamin C pharmacokinetics: implications for oral and intravenous use, Ann.
Intern. Med. 140 (7) (2004) 533–537.
[14] M. Kletzel, K. Powers, M. Hayes, Scurvy: a new problem for patients with
chronic GVHD involving mucous membranes; an easy problem to resolve,
Pediatr. Transpl. 18 (5) (2014) 524–526.
